PDCD1 and neoplasm: Whole-genome sequencing of tumors has revealed that growing tumors acquire hundreds of somatic tumor specific mutations, which form new antigens designated "neoantigens" which have been seen in mouse tumor models and in CTLA-4 and PD-1 treated patients[100–102].These neoantigens are key determinants in the response of patients to PD-1 and CTLA-4 checkpoint immunotherapy[102–103].